Related posts
Oil and stocks climb on earnings week3 Best U.S. Healthcare ETFsOur 3 defensive healthcare stocks picksThis summary was created by AI, based on 5 opinions in the last 12 months.
Becton Dickinson (BDX-N) is the largest player in the medical disposables sector with a 25% market share and a market cap of over $60 billion. The company's growth was impacted by the COVID pandemic but is now accelerating, with solid profits indicating room for acquisitions and share buybacks. Despite recent share stagnation, experts believe the stock is undervalued and offers compelling value. With a strong reach and unique position in the market, Becton Dickinson is expected to see double-digit earnings growth ahead.
Still really likes it. Major issue was surgeries on hold during Covid. Revenues declined, now returning to growth. Free cashflow yield ~4.5%. Earnings growth should return to double digits by end of 2024 and into the next couple of years. Unique. Compelling value.
Avoid TMO because their revenues are flattening. Both trade at a high PE. BDX hasn't done much in share movement. He'd rather pay more for Boston Scientific which performs better.
Share have been flattened, but it's now cheap. They tell a good story.
They have incredible reach with 90% of hospital patients touching one of their surgical and medical products
Pays a good dividend, is held by institutions, great earnings and has global exposure.
Healthcare supplier in North America.
90% of products are disposable - creates recurring revenue.
Expecting double digit earnings growth.
Fantastic M&A growth with good management team.
Dividend growing at a regular pace.
Becton Dickinson is a American stock, trading under the symbol BDX-N on the New York Stock Exchange (BDX). It is usually referred to as NYSE:BDX or BDX-N
In the last year, 4 stock analysts published opinions about BDX-N. 3 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Becton Dickinson.
Becton Dickinson was recommended as a Top Pick by on . Read the latest stock experts ratings for Becton Dickinson.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
4 stock analysts on Stockchase covered Becton Dickinson In the last year. It is a trending stock that is worth watching.
On 2024-11-22, Becton Dickinson (BDX-N) stock closed at a price of $224.
With a market cap of over $60 billion it is the largest player in the medical disposables sector with 25% market share. Growth stalled for two years during COVID but is accelerating now. Its profits are solid so there is lots of room for acquisitions and a start to buying back shares. Trades at 17X earnings and there should be double digit earnings growth ahead. Can be somewhat volatile. Buy 16 Hold 2 Sell 0
(Analysts’ price target is $281.00)